Clinical Trials Logo

Urothelial Carcinoma Bladder clinical trials

View clinical trials related to Urothelial Carcinoma Bladder.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT06331299 Not yet recruiting - Bladder Cancer Clinical Trials

A Phase 3 Study of UGN-103 for Treatment of Patients With Low-grade Intermediate-risk Non-muscle Invasive Bladder Cancer

UTOPIA
Start date: July 2024
Phase: Phase 3
Study type: Interventional

This Phase 3, single-arm, multicenter study will evaluate the efficacy and safety of UGN-103, a novel formulation of UGN-102, instilled in the urinary bladder of patients with low-grade non-muscle invasive bladder cancer (LG-NMIBC).

NCT ID: NCT05701332 Not yet recruiting - Clinical trials for Urothelial Carcinoma Bladder

Effect of Intravesical B.C.G and Gemcitabine on Semen Quality and Testicular Volume

Start date: April 1, 2023
Phase: Phase 4
Study type: Interventional

To evaluate the effects of local intravesical B.C.G and gemcitabine on semen quality and testicular volume.

NCT ID: NCT05656235 Not yet recruiting - Bladder Cancer Clinical Trials

Renal Retention in High Grade Upper Tract Urothelial Cancer

Start date: July 2024
Phase: Phase 2
Study type: Interventional

This trial will evaluate the use of combination pembrolizumab and enfortumab vedotin for patients with high grade non-metastatic (cN0/NxMx, no measurable regional lymph nodes, no metastases) upper tract urothelial cancer (UTUC), preferring to forego standard of care radical nephroureterectomy (RNU) surgery. Currently these patients would not be suitable candidates for neoadjuvant trials, as the patients intention is to forego surgery. The patients are also not candidates for metastatic trials, as the patients have no measurable metastasis. The Investigators hypothesize the combination of pembrolizumab and enfortumab vedotin for patients with high grade cN0/NxMx UTUC deferring RNU will lead to event free survival outcomes similar to that achieved by RNU in a historic dataset.

NCT ID: NCT05037279 Not yet recruiting - Bladder Cancer Clinical Trials

Evaluating Safety and Efficacy of Verity-BCG in BCG-naïve Patients With Intermediate and High-risk Non-muscle Invasive Bladder (NMIBC)

EVER
Start date: January 1, 2023
Phase: Phase 3
Study type: Interventional

The aim of this study is to evaluate the effect of Verity-BCG in patients with intermediate and high-risk non-muscle-invasive bladder cancer (NMIBC) and to compare our findings to the standard of care BCG formulation, OncoTICE (BCG) in order to examine our hypothesis that Verity-BCG is at least non-inferior to OncoTICE in achieving 24-month Recurrence Free Survival in NMIBC patients who are at high risk of recurrence and have never been treated with intradermal or intravesical BCG before, with the exception of tuberculosis vaccination in childhood.